Building a Biotech Pipeline for Aesthetics and Therapeutics
Ep. 106 - Conor Gallagher of Revance
39 minute view/listen
Aug 2024
Available everywhere you podcast
As the Chief Scientific Officer at Revance, Conor Gallagher spearheads R&D, process and analytical development under the umbrella of scientific innovation while also leading a team working on Revance's biosimilar program.
With the stated goal of setting a "new standard in healthcare by elevating patient and physician experiences," Revance boasts an impressive lineup of aesthetic and therapeutic offerings. Notable among these are the RHA Collection of dermal fillers, designed to adapt to dynamic facial movements for natural-looking results, and Daxxify, a long-lasting/fast-acting neurotoxin for smoothing frown lines that is powered by a novel peptide. What's more, Daxxify was recently approved for FDA approved for the treatment of cervical dystonia in adults.
And the future is looking even brighter with the recent announcement that Revance has entered into a merger agreement with Crown Laboratories to bring together their complementary product lines to create a leading, innovative, high-growth aesthetics and skincare company.
So tune in for a sneak peek at what's next in the biotech pipeline at Revance — and soon to be Crown Laboratories — on the latest episode of The Technology of Beauty.
Subscribe to
The Technology of Beauty
Produced and co-founded by Influx, The Technology of Beauty is the podcast of renowned plastic surgeon Dr. Grant Stevens. Tune in to hear interviews with the innovators and entrepreneurs who are shaping the future of aesthetics from the industry side.
